Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer

Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer

© 2016 Elsevier Inc.Background: The purpose of this study was to evaluate the efficacy of 3 first-line chemotherapy combination regimens for HER2-negative metastatic breast cancer (mBC). Patients and Methods: In this open-label, 3-arm, randomized phase II trial, patients were randomized to all-oral...

Full description

Bibliographic Details
Main Authors: Cinieri, S., Chan, Arlene, Altundag, K., Vandebroek, A., Tubiana-Mathieu, N., Barnadas, A., Dodyk, P., Lazzarelli, S., Botha, M., Rauch, D., Villanova, G., Coskun, U.
Format: Journal Article
Published: 2017
Online Access:http://hdl.handle.net/20.500.11937/58481

Internet

http://hdl.handle.net/20.500.11937/58481

Similar Items